17566601

Source:http://linkedlifedata.com/resource/pubmed/id/17566601

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0033681, umls-concept:C0242379, umls-concept:C1122962, umls-concept:C1135135, umls-concept:C1280477, umls-concept:C1522634
pubmed:issue	2
pubmed:dateCreated	2007-7-16
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8800805
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Protein-Tyrosine Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor, http://linkedlifedata.com/resource/pubmed/chemical/erlotinib, http://linkedlifedata.com/resource/pubmed/chemical/gefitinib
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	0169-5002
pubmed:author	pubmed-author:CostaDaniel BDB
pubmed:issnType	Print
pubmed:volume	57
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	251-2
pubmed:dateRevised	2009-11-19
pubmed:meshHeading	pubmed-meshheading:17566601-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17566601-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:17566601-Disease Progression, pubmed-meshheading:17566601-Drug Resistance, Neoplasm, pubmed-meshheading:17566601-Enzyme Inhibitors, pubmed-meshheading:17566601-Humans, pubmed-meshheading:17566601-Lung Neoplasms, pubmed-meshheading:17566601-Mutation, pubmed-meshheading:17566601-Protein-Tyrosine Kinases, pubmed-meshheading:17566601-Quinazolines, pubmed-meshheading:17566601-Receptor, Epidermal Growth Factor
pubmed:year	2007
pubmed:articleTitle	To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.
pubmed:publicationType	Letter